Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Under-the-skin Tepezza comparable to infused version in key study, Amgen says
Amgen has announced that an injectable, on-body injector version of its thyroid eye disease drug, Tepezza, demonstrated comparable efficacy to the infused version in a Phase 3 trial. This subcutaneous option, named Tepezza OBI, could help Amgen maintain market leadership against emerging rivals and potentially expand market access by offering a more convenient treatment. The company expects to disclose full study results at an upcoming medical meeting, with analysts noting the critical role of competitive convenience and safety profiles for market positioning.